Table 5.
League table presenting pairwise treatment comparisons in mean difference (95% CrI) for change in mean SBP (mmHg) from baseline
| Cana100 | Cana300 | Dapa10 | Dapa10/Saxa5 | Dapa5 |
|---|---|---|---|---|
| Cana100 | 1.29 (− 0.37, 2.95) | − 1.29 (− 2.95,0.37) | − 2.09 (− 5.35, 1.19) | − 1.87 (− 4.46, 0.77) |
| Cana300 | − 2.47 (− 5.07, 0.14) | − 3.37 (− 6.65, − 0.09) | − 3.15 (− 5.75, − 0.49) | |
| Dapa10 | − 0.90 (− 3.35, 1.55) | − 0.67 (− 2.52, 1.17) | ||
| Dapa10/Saxa5 | 0.22 (− 2.37, 2.82) | |||
| Dapa5 |
| Cana100 | Dapa5/Saxa5 | Empa10 | Empa25 | Ertu15 |
|---|---|---|---|---|
| Cana100 | − 1.81 (− 4.70, 1.12) | − 1.25 (− 3.96, 1.48) | − 0.54 (− 3.24, 2.19) | 1.26 (− 1.18, 3.74) |
| − 3.10 (− 5.98, − 0.16) | − 2.54 (− 5.26, 0.21) | − 1.84 (− 4.59, 0.93) | − 0.03 (− 2.50, 2.44) | |
| − 0.62 (− 2.87, 1.62) | − 0.05 (− 2.63, 2.54) | 0.65 (− 1.95, 3.24) | 2.45 (− 0.72, 5.61) | |
| 0.28 (− 2.52, 3.07) | 0.86 (− 2.44, 4.14) | 1.55 (− 1.76, 4.85) | 3.36 (− 0.41, 7.14) | |
| 0.06 (− 1.64, 1.76) | 0.62 (− 2.03, 3.26) | 1.32 (− 1.34, 3.96) | 3.12 (− 0.09, 6.34) | |
| Dapa5/Saxa5 | 0.56 (− 2.38, 3.52) | 1.27 (− 1.69, 4.17) | 3.05 (− 0.39, 6.52) | |
| Empa10 | 0.70 (− 1.22, 2.65) | 2.50 (− 0.80, 5.81) | ||
| Empa25 | 1.81 (− 1.51, 5.11) |
| Cana100 | Ertu15/Sita100 | Ertu5 | Ertu5/Sita100 | PBO |
|---|---|---|---|---|
| Cana100 | 0.97 (− 1.59, 3.57) | 0.92 (− 1.53, 3.41) | 0.71 (− 1.88, 3.30) | − 5.34 (− 7.26, − 3.41) |
| − 0.32 (− 2.91, 2.28) | − 0.37 (− 2.85, 2.11) | − 0.57 (− 3.20, 2.03) | − 6.63 (− 8.57, − 4.66) | |
| 2.16 (− 1.13, 5.41) | 2.11 (− 1.10, 5.28) | 1.91 (− 1.40, 5.17) | − 4.15 (− 5.87, − 2.45) | |
| 3.06 (− 0.79, 6.88) | 3.01 (− 0.76, 6.79) | 2.80 (− 1.05, 6.67) | − 3.24 (− 5.90, − 0.60) | |
| 2.84 (− 0.45, 6.11) | 2.78 (− 0.46, 6.01) | 2.57 (− 0.74, 5.89) | − 3.48 (− 5.27, − 1.69) | |
| 2.77 (− 0.74, 6.30) | 2.72 (− 0.73, 6.16) | 2.51 (− 1.02, 6.06) | − 3.53 (− 5.72, − 1.36) | |
| 2.21 (− 1.16, 5.59) | 2.16 (− 1.13, 5.45) | 1.95 (− 1.47, 5.37) | − 4.10 (− 6.03, − 2.17) | |
| 1.51 (− 1.91, 4.90) | 1.47 (− 1.88, 4.74) | 1.26 (− 2.16, 4.66) | − 4.80 (− 6.73, − 2.86) | |
| − 0.29 (− 2.11, 1.53) | − 0.34 (− 1.58, 0.92) | − 0.55 (− 2.37, 1.29) | − 6.60 (− 9.28, − 3.92) | |
| Ertu15/Sita100 | − 0.05 (− 1.86, 1.76) | − 0.26 (− 2.23, 1.71) | − 6.31 (− 9.09, − 3.51) | |
| Ertu5 | − 0.21 (− 2.03, 1.60) | − 6.27 (− 8.95, − 3.57) | ||
| Ertu5/Sita100 | − 6.06 (− 8.87, − 3.23) | |||
| PBO |
| Cana100 | Saxa2.5 | Saxa5 | Sema14 | Sita100 |
|---|---|---|---|---|
| Cana100 | − 4.25 (− 7.90, − 0.61) | − 3.86 (− 6.39, − 1.28) | − 0.54 (− 3.97, 2.94) | − 2.02 (− 3.70, − 0.35) |
| − 5.55 (− 9.18, − 1.90) | − 5.15 (− 7.71, − 2.56) | − 1.84 (− 5.26, 1.64) | − 3.32 (− 4.97, − 1.64) | |
| − 3.06 (− 6.37, 0.23) | − 2.67 (− 4.42, − 0.92) | 0.65 (− 2.70, 3.98) | − 0.83 (− 3.45, 1.74) | |
| − 2.17 (− 5.91, 1.58) | − 1.77 (− 4.09, 0.53) | 1.55 (− 2.38, 5.45) | 0.07 (− 3.23, 3.35) | |
| − 2.39 (− 5.63, 0.84) | − 2.00 (− 3.48, − 0.53) | 1.33 (− 2.07, 4.68) | − 0.16 (− 2.82, 2.46) | |
| − 2.44 (− 5.87, 0.97) | − 2.05 (− 3.74, − 0.37) | 1.27 (− 2.36, 4.85) | − 0.22 (− 3.18, 2.68) | |
|
− 3.01 (− 6.64, 0.62) |
− 2.62 (− 5.23, − 0.04) | 0.70 (− 2.17, 3.54) | − 0.77 (− 3.53, 1.96) | |
| − 3.71 (− 7.36, − 0.10) | − 3.32 (− 5.90, − 0.72) | 0.00 (− 2.11, 2.11) | − 1.47 (− 4.25, 1.26) | |
| − 5.50 (− 9.57, − 1.42) | − 5.13 (− 8.30, − 1.93) | − 1.81 (− 5.71, 2.11) | − 3.29 (− 5.12, − 1.46) | |
| − 5.22 (− 9.37, − 1.06) | − 4.84 (− 8.09, − 1.55) | − 1.52 (− 5.48, 2.50) | − 3.00 (− 4.98, − 1.01) | |
| − 5.16 (− 9.26, − 1.08) | − 4.78 (− 7.97, − 1.58) | − 1.48 (− 5.37, 2.51) | − 2.94 (− 4.78, − 1.12) | |
| − 4.96 (− 9.12, − 0.80) | − 4.57 (− 7.88, − 1.30) | − 1.26 (− 5.23, 2.78) | − 2.74 (− 4.73, − 0.73) | |
| 1.09 (− 2.00, 4.16) | 1.48 (− 0.23, 3.17) | 4.80 (1.94, 7.65) | 3.31 (1.34, 5.26) | |
| Saxa2.5 | 0.39 (− 2.62, 3.42) | 3.71 (− 0.49, 7.89) | 2.23 (− 1.45, 5.85) | |
| Saxa5 | 3.32 (− 0.04, 6.63) | 1.84 (− 0.78, 4.40) | ||
| Sema14 | − 1.47 (− 4.97, 1.96) | |||
| Sita100 |
The results presented in the table correspond to pairwise comparison of the treatment in the row vs. the treatment in the column. Posterior median of mean difference is presented with 95% credible interval. For difference in mean change from baseline, lower values (< 0) indicate more favorable results. For example, the mean difference for Cana100 vs. placebo is − 5.34, indicating Cana100 had a 5.34 mmHg greater reduction in systolic blood pressure than placebo. Credible intervals not including 0 indicate statistically significant differences, which are highlighted in bold in the table
Cana canagliflozin, Dapa dapagliflozin, Empa empagliflozin, Ertu ertugliflozin, N/A not applicable, Pbo placebo, Saxa saxagliptin, SBP systolic blood pressure, Sema semaglutide, Sita sitagliptin